Tag: Indian Institute of Science

  • IISc researchers provide alternative mechanism to render viruses like SARS-CoV-2 inactive

    By PTI

    BENGALURU: Researchers at the Indian Institute of Science have developed a new approach that provides an alternative mechanism to render viruses like SARS-CoV-2 inactive, according to IISc.

    In a study published in ‘Nature Chemical Biology, the researchers report the design of a new class of artificial peptides or mini proteins that can not only block virus entry into our cells but also clump virions (virus particles) together, reducing their ability to infect.

    A protein-protein interaction is often like that of a lock and a key, the Bengaluru-based IISc noted in a statement.

    This interaction can be hampered by a lab-made mini protein that mimics, competes with, and prevents the ‘key’ from binding to the ‘lock’, or vice versa.

    In the new study, the team has exploited this approach to design mini proteins that can bind to, and block the spike protein on the surface of the SARS-CoV-2 virus.

    This binding was further characterized extensively by cryo-electron microscopy (cryo-EM) and other biophysical methods.

    These mini proteins are helical, hairpin-shaped peptides, each capable of pairing up with another of its kind, forming what is known as a dimer.

    Each dimeric ‘bundle’ presents two ‘faces’ to interact with two target molecules.

    The researchers hypothesized that the two faces would bind to two separate target proteins, locking all four in a complex and blocking the targets’ action.

    “But we needed proof of principle,” says Associate Professor in the Molecular Biophysics Unit (MBU), IISc, and the lead author of the study, Jayanta Chatterjee.

    The team decided to test their hypothesis by using one of the mini proteins called SIH-5 to target the interaction between the Spike (S) protein of SARS-CoV-2 and ACE2 protein in human cells.

    The S protein is a trimer, a complex of three identical polypeptides.

    Each polypeptide contains a Receptor Binding Domain (RBD) that binds to the ACE2 receptor on the host cell surface.

    This interaction facilitates viral entry into the cell.

    The SIH-5 mini protein was designed to block the binding of the RBD to human ACE2.

    When a SIH-5 dimer encountered an S protein, one of its faces bound tightly to one of the three RBDs on the S protein trimer, and the other face bound to an RBD from a different S protein.

    This ‘cross-linking’ allowed the mini protein to block both S proteins at the same time, the statement said.

    “Several monomers can block their targets,” says Chatterjee.

    “(But) cross-linking of S proteins blocks their action many times more effectively. This is called the avidity effect.”

    Under cryo-EM, the S proteins targeted by SIH-5 appeared to be attached head-to-head.

    “We expected to see a complex of one spike trimer with SIH-5 peptides. But I saw a structure that was much more elongated,” says Assistant Professor at MBU and one of the corresponding authors, Somnath Dutta.

    Dutta and the others realised that the spike proteins were being forced to form dimers and clumped into complexes with the mini protein.

    This type of clumping can simultaneously inactivate multiple spike proteins of the same virus and even multiple virus particles.

    “I have worked with antibodies raised against the spike protein before and observed them under a cryo-EM. But they never created dimers of the spikes,” says Dutta.

    The mini protein was also found to be thermostable, it can be stored for months at room temperature without deteriorating.

    The next step was to ask if SIH-5 would be useful for preventing COVID-19 infection.

    To answer this, the team first tested the mini protein for toxicity in mammalian cells in the lab and found it to be safe.

    Next, in experiments carried out in the lab of Raghavan Varadarajan, a Professor at MBU, hamsters were dosed with the mini protein, followed by exposure to SARS-CoV-2.

    These animals showed no weight loss and had greatly decreased viral load as well as much less cell damage in the lungs, compared to hamsters exposed only to the virus.

    The researchers believe that with minor modifications and peptide engineering, this lab-made mini protein could inhibit other protein-protein interactions as well.

  • DST-funded start-ups develops electrochemical ELISA test for Covid antibody concentration

    By PTI
    NEW DELHI: A Bengaluru-based start-up has developed a novel, point-of-care electrochemical ELISA test that enables fast and accurate estimation of total antibody concentration of COVID-19 in clinical samples, the Department of Science and Technology (DST) said on Saturday.

    PathShodh Healthcare, the start-up incubated at the Society for Innovation and Development (SID), Indian Institute of Science (IISc), has made a very significant breakthrough to develop the first-of-its-kind, semi-quantitative electrochemical ELISA test for COVID-19 IgM and IgG antibodies.

    While qualitative analysis detects constituent elements in the sample, semi-quantitative analysis gives an approximate estimation of their concentrations.

    PathShodh has received the licence to manufacture for sale from the Central Drugs Standard Control Organisation (CDSCO) after validation at Translational Health Science and Technology Institute (THSTI), Faridabad, the DST said.

    This novel technology and product was supported by the Department of Science and Technology (DST) under its initiative on Centre for Augmenting WAR with COVID-19 Health Crisis (CAWACH).

    The effort was coordinated through SINE at IIT Bombay and IKP Knowledge Park, Hyderabad.

    The test kit comes in two parts.

    One is the hand-held analyser which reads the blood sample and gives a detailed report.

    The other is a test strip where a drop of blood from one’s fingertip is inserted into the device.

    The hand-held device provides the results within five minutes, the results of which can be downloaded on your mobile phone.

    It has been developed, leveraging PathShodh’s Lab-on-Palm platform “anuPathTM”, which interfaces with disposable test strips functionalized with immunoreceptors specific to COVID-19 antibodies, it added.

    As the results are automatically displayed by the hand-held reader, there are no subjective errors due to the manual readout of test results.

    The other unique features of this technology include onboard memory to store more than 1 lakh real-time test results, touch screen display, rechargeable battery, Bluetooth connectivity to smart phone and cloud storage, capabilities to map the patient data to Aadhaar number, and the possibility of connecting test data through APIs to Aarogya Setu, it added.